Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779048 · ClinicalTrials.gov registry record · Phase 4
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 147
- Enrollment target
NCT03779048: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT03779048 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 147 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03779048, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss medication to BT improves 24-week weight loss, as compared to BT with placebo, in subjects identified as having suboptimal early weight loss after 4 weeks of individual behavioral weight control. All participants, regardless of their early weight loss, will receive the same BT program of diet, physical activity, and behavior therapy for weight loss for an additional 24 weeks (28 total weeks of treatment).
Primary Outcome
Co-primary outcomes - phase 1
Interventions
- DRUG Placebo
- BEHAVIORAL Behavioral Treatment
- DRUG Phentermine 15 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2022-05-25 |
| Phase | Phase 4 |
What the finished NCT03779048 record still lists
NCT03779048 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03779048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03779048 about?
NCT03779048 is a clinical study titled "Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment". This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss medication to BT improves...
What is the current status of trial NCT03779048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 147 participants. The study started on 2019-07-15. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03779048?
The interventions under investigation include: Placebo (DRUG), Behavioral Treatment (BEHAVIORAL), Phentermine 15 MG (DRUG).
Who is sponsoring clinical trial NCT03779048?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03779048's enrollment target sits among peer trials
147 570th of 2000 higher than 1,430 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI